News Verily plans digital ophthalmology joint venture with Santen Verily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen.
News Oxford Biomedica signs ophthalmology R&D deal with Santen UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Partner Content Partner Content Queen's University Belfast and Santen to Present Opening Key... Ophthalmic Drugs Conference London
Events Partner Content Ophthalmic Drugs - Europe's Leading Ophthalmic Conference Ophthalmic Drugs Conference
Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
